Aria F. Olumi, MD

Associate Professor, Department of Surgery, Harvard Medical School

Director, Urology Research Program, Genitourinary Oncology Unit, Massachusetts General Hospital

Contact Info

Aria Olumi
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Mailstop: Yawkey, Suite 7E
Phone: 617-643-0237
Fax: 617-643-4019
aolumi@partners.org

Assistant

Francine O'Reilly
Administrative Assistant
Urology
Massachusetts General Hospital
55 Fruit St.
Boston, MA, 02114
Phone: 617-643-0237
Fax: 617-643-4019
foreilly@partners.org

DF/HCC Program Affiliation

Kidney Cancer
Prostate Cancer

Research Abstract

TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells.

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Aria F. Olumi, MD Associate Professor, Department of Surgery, Harvard Medical School Director, Urology Research Program, Genitourinary Oncology Unit, Massachusetts General Hospital Contact Info Aria Olumi Massachusetts General Hospital 55 Fruit Street Boston, MA, 02114 Mailstop: Yawkey, Suite 7E Phone: 617-643-0237 Fax: 617-643-4019 aolumi@partners.org Assistant Francine O'Reilly Administrative Assistant Urology Massachusetts General Hospital 55 Fruit St. Boston, MA, 02114 Phone: 617-643-0237 Fax: 617-643-4019 foreilly@partners.org DF/HCC Program Affiliation Kidney Cancer Prostate Cancer Research Abstract TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells. Publications View All Publications
Site Map Site Feedback Web Privacy Policy